

Receipt date: 01/27/2009

JAN. 27. 2009 10:50AM

(3) FISH & RICHARDSON 6175428906

RECEIVED
CENTRAL FAX CENTER

NO. 1840 P. 6
JAN 27 2009 Sheet 2 of 2

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 06275-0160002	Application No. 09/993,669
	Applicant Ann-Kristin Karlsson et al.			
	Filing Date November 27, 2001		Group Art Unit 1623	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	1	Product description for Rhinocort Aqua® (budesonide), Nasal Spray 32 mcg, 2 pages, dated 01/05
	2	Pulmicort Turbuhaler® (budesonide inhalation powder), 4 pages, dated 10/06
	3	Astra Draco Specification for micronized budesonide prepared for use in the Rhinocort Aqua® nasal spray product, 2 pages, dated 11/20/95
	4	Astra Draco Specification for budesonide prepared for use in the Pulmicort Turbuhaler® product, 2 pages, dated 04/01/97
	5	US Pharmacopeia 23/NF18, pages 1686-1690 and 1963-1975, published by United States Pharmacopeial Convention, Inc., Rockville, MD (1995)
	6	Specification for Pulmicort Respules®, 3 pages, GEL Version ID: RITA.000-243-420.3.0, printed on 06/15/08
	7	US Pharmacopeia 23, "Microbial Limit Tests" USP <61>, pages 1681-1686, published by United States Pharmacopeial Convention, Inc., Rockville, MD (1995)
	8	Astra Draco Specification for PULMICORT 200 TURBUHALER®, 5 pages, dated 09/17/97
	9	Astra Draco Specification for RHINOCORT® nasal spray, 1 page, dated 04/225/91
	10	"Guidance for Industry: Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation—Small Entity Compliance Guide," U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 4 pages, November 2001
	11	Pulmicort Respules® (budesonide inhalation suspension) product information, 6 pages, dated 6/07
	12	Astra Draco Specification for Pulmicort® suspension for Nebulizing product, 2 pages, dated 02/23/1994
	13	Recorded minutes of a 11/20/96 pre-NDA meeting attended by Astra USA, Astra Draco, and FDA officials, 6 pages
	14	Astra Draco Specification for "budesonide micronized sterile", 2 pages, dated 11/18/1983
	15	Astra Draco documentation (in Swedish) of Manufacturing Method for Preferid® cream dated 09/09/1980, 5 pages, and English translation, 5 pages
	16	Internal Astra Draco document "Establishment of limits for content and related foreign steroids in budesonide substance" dated 03/26/1980, 5 pages
	17	Internal Astra Draco document "Limits for content and related foreign steroids in budesonide substance," dated 11/04/1980
	18	Internal Astra Draco document "Analytical Certificate", dated 08/28/1980, in Swedish, 1 page, with English translation, 1 page
	19	Internal Astra Draco document "Analytical Certificate", dated 09/14/1978, in Swedish, 1 page, with English translation, 1 page
	20	Internal Astra Draco document "Analytical Certificate", dated 02/28/1980, in Swedish, 1 page, with English translation, 1 page
	21	Internal Astra Draco document "Analytical Certificate", dated 02/28/1980, in Swedish, 1 page, with English translation, 1 page
Examiner Signature /Leigh Maier/		Date Considered 01/30/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Disclosure Form (PTO-1449)

PAGE 6/7 * RCVD AT 1/27/2009 10:45:50 AM [Eastern Standard Time] * SVR:USPTO-EFXXF-6/35 * DNIS:2730656 * CSID:6175428906 * DURATION (mm:ss):02:38

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0160002	Application No. 09/993,669
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Ann-Kristin Karlsson et al.	
		Filing Date November 27, 2001	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	22	Internal Astra Draco document "Analytical Certificate", dated 03/28/1980, in Swedish, 1 page, with English translation, 1 page
	23	Internal Astra Draco document "Analytical Certificate", dated 03/28/1980, in Swedish, 1 page, with English translation, 1 page
	24	Internal Astra Draco document "Analytical Certificate", dated 06/09/1980, in Swedish, 1 page, with English translation, 1 page
	25	Internal Astra Draco document "Analytical Certificate", dated 05/04/1979, in Swedish, 1 page, with English translation, 1 page
	26	Internal Astra Draco document "Analytical Certificate", dated 05/04/1979, in Swedish, 1 page, with English translation, 1 page
	27	Internal Astra Draco document "Analytical Certificate", dated 05/08/1979, in Swedish, 1 page, with English translation, 1 page
	28	Internal Astra Draco document "Analytical Certificate", dated 12/12/1978, in Swedish, 1 page, with English translation, 1 page

Examiner Signature /Leigh Maier/	Date Considered 01/30/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)